May 26th, 2023 (Shanghai) — We are glad to announce that Dr. Hongkai Chen, the CEO of Elixiron, has been invited to present at ACCESS CHINA Boston Forum on June 4th. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the western biopharma industry.
Please contact us if you would like to have 1 on 1 meeting with Elixiron.
About Elixiron
Elixiron Immunotherapeutics Ltd. is dedicated to the research and development of innovative immunotherapy drugs with a focus on originality and has established clinical and research centers in Shanghai, Taipei, and Lausanne (Switzerland). The company owns a globally leading independent research and development platform which is backed by intellectual property rights. Pipelines in developing include innovative immune therapies targeting unmet medical needs such as vitiligo, Alzheimer’s, and tumors, aiming to be the best and first in class (BIC/FIC). The neurological disease development projects of the company have twice been awarded by the Alzheimer’s Association: in 2020 (partnership with Microsoft co-founder Bill Gates) the Part-The-Cloud-Gates award, as well as in 2022 the Part-The-Cloud Award. Elixiron is the only company in Asia to receive this honor. Currently, the company has two products in Phase II clinical trials and has obtained orphan drug designation from the U.S. FDA for the treatment of idiopathic pulmonary fibrosis (IPF) and for treating hemophagocytic lymphohistiocytosis (HLH). It is Elixiron’s endeavor to engage in global forward-looking biotechnological R&D and applications, continuously strengthening its core competitiveness in innovative immunotherapy.
公司简介
安立玺荣生物医药专注于源头创新的免疫治疗新药研发，拥有全球领先的自主研发平台与自主知识产权。开发针对白癜风、阿尔兹海默、肿瘤等 BIC/FIC(Best/First In Class)创新性免疫疗法。目前在上海，瑞士洛桑和台北分别设有临床及研发中心；公司两次荣膺微软集团创始人比尔盖兹(Bill Gates)与美国阿尔兹海默症协会(Alzheimer’s Association)合作的 Part The Cloud-Gates Partnership 学术科学奖项(亚洲唯一获此殊荣)以及PTC 全球神经疾病研发项目奖励。公司目前已有两个产品进入临床II期阶段，并获得美国FDA关于IPF和HLH两个疾病的孤儿药认定。安立玺荣生物医药将持续进行全球前瞻性生物技术与创新应用的研发，不断巩固在创新性免疫疗法的核心竞争力。
About the speaker
Dr. Chen is an internationally renowned expert in the research and development of novel drugs for neurodegenerative diseases, with 25 years of experience spanning academic research, drug development, and clinical translational medicine. Dr. Chen has led a team that has twice been, the only recipients in Asia, recognized and funded by the Part-The-Cloud New Drug Development Award Program, a collaboration between the Alzheimer’s Association and the Bill Gates Foundation. This funding has been utilized to advance cutting-edge drug development for Alzheimer’s disease. Prior to returning to China, Dr. Chen served as an assistant professor at the Gladstone Institutes, University of California, San Francisco, where he collaborated with Merck Pharmaceuticals on the development of new drugs for Alzheimer’s disease. He has also worked with several biopharmaceutical research institutions, including GlaxoSmithKline, leading the research and development of multiple novel drugs in the field of neurodegenerative diseases from early-stage development to clinical trials. The research achievements of Dr. Chen and his team have published multiple times in top international scientific journals such as Cell and Nature Medicine, and they hold several patents for new drug inventions. Elixiron Immunotherapuetics is dedicated to the development of new drugs for the treatment of immune and neurological diseases. The company has already advanced two products to the Phase II clinical development stage.
专家简介
陈博士为国际知名的神经退化疾病新药研发专家，具有二十五年横跨学术研究、药物开发以及临床转化医学经验。陈博士带领团队曾两度亚洲唯一获得美国阿尔兹海默协会及比尔盖茨基金会合作设立的Part the Cloud新药研发奖助计划认定及资助，用于推动阿尔兹海默症的前沿新药研发。在回国前，陈博士任职于美国加州大学旧金山分校格拉斯通研究所担任助理教授，期间与美国默克药厂合作进行了阿尔兹海默症的新药研发。之后曾服务于葛兰素史克等多家生物医药研发机构，带领从早期研发到临床试验多项神经疾病领域新药的项目研发。陈博士和团队的研究成果曾多次被发表在包括 Cell及Nature Medicine等国际顶尖科学期刊并拥有多项新药发明专利。安立玺荣生物医药致力于治疗免疫及神经疾病的新药研发，目前公司已经有两项产品推进到临床II期开发阶段。
About ACCESS CHINA Boston Forum
“ACCESS CHINA – Boston Forum @BIO” is scheduled to be held on June 4th and June 13th-15th, 2023, in Boston and online, respectively. This event is expected to be the largest Asia-themed gathering during the BIO Convention 2023. The main theme of the forum is “Building Effective Partnerships in Asia: Strategies for Collaboration and Growth”. During the forum, we will cover a range of key topics include drug innovation, market trends, partnership models, and best practices for successful collaborations, etc.
Conference Name: ACCESS CHINA – Boston Forum @BIO
Date & Time: June 4, Sun. (Boston) and June 13-15 (Online)
Content: Keynote Speeches, Panel Discussion, Company Presentations, ChemPartner-ACCESS CHINA Dinner Reception
Scale: Expected 1000 participants Online, 150 participants onsite; 100 company roadshows
Participants: Pharma/Biotech senior management and BDs, investors.
View more information at https://biotochina.org/
关于药通中国-波士顿论坛
“ACCESS CHINA 药通中国-波士顿论坛@BIO”将于2023年6月4-15日在波士顿及线上举行的。此次论坛将是BIO Convention 2023大会期间最大的亚洲主题交流活动。在过去3年时间，药通中国已成功举办13届线上线下活动，帮助近千家公司在药通平台上展出。
大会名称：药通中国-波士顿论坛@BIO
大会日期：2023.6.4（周日，波士顿） 2023.6.13-15（线上）
大会内容：主题演讲、圆桌讨论、海内外优质项目路演、睿智医药-药通中国招待晚宴
大会规模：预计线上1000参会者； 线下150参会者; 100场公司路演
参会观众：海内外医药企业（药企及Biotech）高管及BD、基金高管
查看更多信息： https://biotochina.org/
MORE INFORMATION
Contact US
Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact:
Wendi Xiang
Wxiang@yafocapital.com
BioToChina.org 